With the spread of AIDS, many HIV-1 infected women and children have been diagnosed with Kaposi's sarcoma (KS), mostly in Africa. Since the discovery of the causative agent of KS (human herpesvirus 8, HHV-8) several seroepidemiological studies have been conducted to identify groups at risk of KS. The present study was conducted in order to add some information from São Paulo, Brazil. We searched for HHV-8 antibodies in plasma samples obtained from a cohort of 108 children born to HIV-1 infected mothers, and from 15 mother-child pairs enrolled in a longitudinal study of HIV-1 vertical transmission. An in house immunofluorescence assay was used to detect anti-latent and anti-lytic HHV-8 antibodies based on the BCBL-1 cell line. No case of anti-latent antibodies and a 7.4 per cent frequency of anti-lytic antibodies were detected among children. Interestingly, the detection of HHV-8 antibodies varied according to the children's HIV-1 status; no antibodies were detected in HIV-1 non-infected children and 10.9 per cent and 8.3 per cent frequencies of antilytic antibodies in truly HIV-1 infected children and in children in whom the HIV-1 status could not be defined. Since concordant results were obtained by the analysis of plasma samples obtained from mother-child pairs and considering the children's age, the antibodies detected in the present study probably reflect maternal antibodies. Unfortunately, we were not able to determine if any case of KS occurred among mothers, but because of the risk of HHV-8 horizontal transmission, the results obtained prompt us to continue investigating groups at risk to acquire HHV-8 and to search for preventive measures to avoid virus transmission.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/tropej/49.4.247 | DOI Listing |
Front Public Health
January 2025
College of Life Sciences, University of Ningxia, Yinchuan, Yinchuan, Ningxia, China.
Background: Over the past decade, sexual transmission has become a dominant source of new HIV-1 infection in China. However, very few studies have been conducted to characterize the two sexual transmissions, homosexual and heterosexual transmission. This study was conducted to better understand the relationship between genotypes, drug resistance, and molecular transmission networks in two groups of sexually transmitted HIV-1 in Ningxia, China.
View Article and Find Full Text PDFJ Antimicrob Chemother
January 2025
Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA.
Background: Lenacapavir, a novel HIV-1 capsid inhibitor, shows promise for treating MDR HIV-1, as well as for pre-exposure prophylaxis (PrEP) in prevention of HIV infection. Its unique mechanism and lack of cross-resistance with other antiretroviral classes make lenacapavir a significant addition to HIV therapy. The clinical trials CALIBRATE and CAPELLA have demonstrated high viral suppression rates in both ART-naive individuals and individuals with MDR HIV-1.
View Article and Find Full Text PDFComput Biol Med
January 2025
Department of Chemistry, Graduate University of Advanced Technology, Kerman, Iran.
Designing and employing enzyme inhibitors against viral enzymes is one of the innovative and efficient approaches to treating viral diseases. These inhibitors can disrupt the viral replication cycle by deactivating vital enzymes, thereby curbing the spread of viral infections by reducing their population. So far, inhibitors have been designed, validated, and introduced for these enzymes.
View Article and Find Full Text PDFClin Infect Dis
January 2025
IQVIA Inc., Falls Church, VA.
PLoS One
January 2025
Faculty of Sciences and Technology (FAST), Laboratory of Biology and Molecular Typing in Microbiology (LBTMM), University of Abomey-Calavi, Atlantic, Benin.
Background: Antiretroviral treatment increases the risk of accumulation of resistance mutations that negatively impact the possibilities of future treatment. This study aimed to present the frequency of HIV-1 antiretroviral resistance mutations and the genetic diversity among children with virological failure in five pediatric care facilities in Benin.
Methods: A cross-sectional study was carried out from November 20, 2020, to November 30, 2022, in children under 15 years of age who failed ongoing antiretroviral treatment at five facilities care in Benin (VL > 3log10 on two consecutive realizations three months apart).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!